Daniel J. George, MD

Articles

Dr. George on the Changing Treatment Landscape in Prostate Cancer

October 23rd 2019

Daniel J. George, MD, discusses the changing treatment landscape in prostate cancer.

Dr. George on Investigational Agents Downstream of the Androgen Receptor in Prostate Cancer

October 17th 2019

Daniel J. George, MD, discusses investigational agents downstream of the androgen receptor in advanced prostate cancer.

Dr. George on the Use of Radium-223 in Prostate Cancer

September 18th 2019

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the use of radium-223 dichloride (Xofigo) in prostate cancer.

Dr. George on Promise of PARP Inhibitors in Prostate Cancer

August 9th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses the promise of PARP inhibitors in prostate cancer.

Dr. George Discusses Next Steps in RCC

April 10th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses next steps for research in renal cell carcinoma (RCC).

Dr. George on the Impact of Immunotherapy on TKIs in RCC

April 3rd 2019

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the impact of immunotherapy on TKIs in renal cell carcinoma (RCC).

Dr. George on Dosing TKIs in RCC

March 20th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses the importance of dosing TKIs properly in patients with renal cell carcinoma (RCC).

Dr. George on Sequential Therapy in Metastatic Prostate Cancer

February 15th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequential therapy in metastatic prostate cancer.

Dr. George on Concerns With Immune-Related Adverse Events in RCC

January 10th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses concerns with immune-related adverse events (irAEs) in renal cell carcinoma (RCC).

Dr. George on Sequencing in Renal Cell Carcinoma

December 18th 2018

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequencing in renal cell carcinoma (RCC).

Dr. George on the Use of Adjuvant Sunitinib in RCC

December 1st 2018

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the use of adjuvant sunitinib (Sutent) in the treatment of patients with renal cell carcinoma (RCC).

Dr. George on Rationale for Abi Race Prostate Cancer Study

September 14th 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the rationale for the Abi Race study looking at men with metastatic castration-resistant prostate cancer.

Dr. George on Results of the Abi Race Study for Prostate Cancer

August 27th 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses results of the Abi Race study for patients with metastatic castration-resistant prostate cancer.

Dr. George Discusses an Analysis of the S-TRAC Study in RCC

August 15th 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses an analysis of the S-TRAC study in renal cell carcinoma.

Dr. George on Results of Abi Race Trial in Prostate Cancer

June 2nd 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the results of the prospective multicenter Abi Race trial, which compared outcomes of African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) and prednisone.

Dr. George on Sunitinib in Renal Cell Carcinoma

October 10th 2013

Daniel J. George, MD, director, GU Oncology, Duke Cancer Institute, discusses the use of sunitinib to treat patients with renal cell carcinoma (RCC).

Dr. George on Critical Clinical Trials in Kidney Cancer

September 30th 2013

Daniel J. George, MD, Director, GU Oncology, Duke Cancer Institute, discusses critical phase III clinical trials in metastatic renal cell carcinoma.

Dr. George on Radium-223 in Combinations for mCRPC

July 17th 2013

Daniel J. George, MD, from the Duke Cancer Institute, discusses the potential to incorporate radium-223 into combination strategies to treat patients with metastatic castation-resistant prostate cancer.

Dr. George on Radium-223 in Advanced Prostate Cancer

June 18th 2013

Daniel J. George, MD, from the Duke Cancer Institute, elaborates on the incorporation of radium-223 into the treatment of patients with metastatic castration-resistant prostate cancer.